6 stories mentioning CAMPUpdated 31d ago
Every FINWIRES story that references CAMP, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Andrew J. Schwab, Director, on August 19, 2026, sold 191,865 shares in Camp4 Therapeutics (CAMP) for $879,719. Following the Form 4 filing with the SEC, Schwab has control over a total of 5,677,226 common shares of the company, with 5,677,226 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1736730/000159854926000007/xslF345X05/form4-08212026_080827.xml
Healthcare stocks eased late Tuesday afternoon with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.2%.The iShares Biotechnology ETF (IBB) also dropped 0.2%.In corporate news, Eli Lilly (LLY) acquired 4E Therapeutics, a neuroscience firm creating chronic-pain treatments. Lilly shares fell 1%.CAMP4 Therapeutics (CAMP) shares jumped 6.1% after JPMorgan upgraded the stock to overweight from neutral and raised its price target to $9 from $5.GSK (GSK) said Health Canada approved Exdensur for severe eosinophilic asthma, which is driven by elevated white blood cells, and for chronic rhinosinusitis with nasal polyps, a condition that causes blockage and inflammation. GSK shares eased 0.1%.Oncolytics Biotech (ONCY) shares climbed 11% after the company received a US patent covering the pelareorep manufacturing process into 2044.
Healthcare stocks edged lower late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) easing 0.1%.The iShares Biotechnology ETF (IBB) was down 0.%.In corporate news, CAMP4 Therapeutics (CAMP) shares jumped past 7% after JPMorgan upgraded the stock to overweight from neutral and raised its price target to $9 from $5.
CAMP4 Therapeutics (CAMP) shares were up over 10% in Tuesday trading after JPMorgan upgraded the stock to overweight from neutral and raised its price target to $9 from $5.Trading volume stood at more than 788,000 shares, compared with a daily average of about 85,000.Price: $4.38, Change: $+0.42, Percent Change: +10.61%
CAMP4 Therapeutics (CAMP) has an average rating of buy and mean price target of $8.36, according to analysts polled by FactSet.
Camp4 Therapeutics (CAMP) has an average rating of buy and mean price target of $7.79, according to analysts polled by FactSet.
